EuroPCR 2022 | Jenavalve Trilogy System: Valve for Severe Aortic Regurgitation

Though the different percutaneous valves have been designed and authorized for aortic stenosis with tricuspid valve, they have often been used to treat aortic regurgitation as an off-label indication.

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

The Jenavalve Trilogy valve has recently received the CE Mark for aortic regurgitation and aortic stenosis. 

This study included 45 patients with severe AR.

Primary end point was technical success with <20 mmHg gradient and >1 AR reduction. Also major cardiac events were analyzed, defined as death, MI, stroke and need for cardiac surgery at discharge. 

Mean age was 77, patients were mostly men, 10 were diabetic, 26 had atrial fibrillation, 13 had CABG, most were in functional class III-IV, 26 had conserved ejection fraction.

STS Score was 7.1%.

All procedures were femoral (37 with conscious sedation) and 2 were post-dilated. 

Read also: EuroPCR 2022 | Galileo Trial: Mortality Predictors after Successful TAVR.

Technical success was seen in all patients. Neither of them crossed over to surgery, there were no deaths, major bleedings, or stroke, 9 required definite pacemaker (23%) and there were 3 minor bleedings. 

Aortic valve area was 2.62 cm2 and mean gradient was 4 mmHg. There were no cases of moderate or severe AR and more than half did not present AR at all. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Impact of Iliofemoral Disease on Post TAVR Clinical Outcomes: HOSTILE Score Validation

At present, transcatheter aortic valve replacement (TAVR) has been shown safe and effective for treating severe symptomatic aortic stenosis in high-surgical-risk patients. Moreover, its...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...